194 related articles for article (PubMed ID: 12702521)
1. Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients.
Bernard-Marty C; Mano M; Paesmans M; Accettura C; Munoz-Bermeo R; Richard T; Kleiber K; Cardoso F; Lobelle JP; Larsimont D; Piccart MJ; Di Leo A
Ann Oncol; 2003 May; 14(5):693-8. PubMed ID: 12702521
[TBL] [Abstract][Full Text] [Related]
2. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.
Piccart MJ; Di Leo A; Beauduin M; Vindevoghel A; Michel J; Focan C; Tagnon A; Ries F; Gobert P; Finet C; Closon-Dejardin MT; Dufrane JP; Kerger J; Liebens F; Beauvois S; Bartholomeus S; Dolci S; Lobelle JP; Paesmans M; Nogaret JM
J Clin Oncol; 2001 Jun; 19(12):3103-10. PubMed ID: 11408507
[TBL] [Abstract][Full Text] [Related]
3. Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study.
de Azambuja E; Paesmans M; Beauduin M; Vindevoghel A; Cornez N; Finet C; Ries F; Closon-Dejardin MT; Kerger J; Gobert P; Focan C; Tagnon A; Dolci S; Nogaret JM; di Leo A; Piccart-Gebhart MJ
J Clin Oncol; 2009 Feb; 27(5):720-5. PubMed ID: 19103732
[TBL] [Abstract][Full Text] [Related]
4. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ
Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
[TBL] [Abstract][Full Text] [Related]
5. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
[TBL] [Abstract][Full Text] [Related]
8. HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
Di Leo A; Larsimont D; Gancberg D; Jarvinen T; Beauduin M; Vindevoghel A; Michel J; Focan CH; Ries F; Gobert PH; Closon-Dejardin MT; Dolci S; Rouas G; Paesmans M; Lobelle JP; Isola J; Piccart MJ
Ann Oncol; 2001 Aug; 12(8):1081-9. PubMed ID: 11583189
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
Levine MN; Bramwell VH; Pritchard KI; Norris BD; Shepherd LE; Abu-Zahra H; Findlay B; Warr D; Bowman D; Myles J; Arnold A; Vandenberg T; MacKenzie R; Robert J; Ottaway J; Burnell M; Williams CK; Tu D
J Clin Oncol; 1998 Aug; 16(8):2651-8. PubMed ID: 9704715
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.
Martin M; Villar A; Sole-Calvo A; Gonzalez R; Massuti B; Lizon J; Camps C; Carrato A; Casado A; Candel MT; Albanell J; Aranda J; Munarriz B; Campbell J; Diaz-Rubio E;
Ann Oncol; 2003 Jun; 14(6):833-42. PubMed ID: 12796019
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
Levine MN; Pritchard KI; Bramwell VH; Shepherd LE; Tu D; Paul N;
J Clin Oncol; 2005 Aug; 23(22):5166-70. PubMed ID: 16051958
[TBL] [Abstract][Full Text] [Related]
13. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.
Poole CJ; Earl HM; Hiller L; Dunn JA; Bathers S; Grieve RJ; Spooner DA; Agrawal RK; Fernando IN; Brunt AM; O'Reilly SM; Crawford SM; Rea DW; Simmonds P; Mansi JL; Stanley A; Harvey P; McAdam K; Foster L; Leonard RC; Twelves CJ;
N Engl J Med; 2006 Nov; 355(18):1851-62. PubMed ID: 17079759
[TBL] [Abstract][Full Text] [Related]
14. Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study.
Colozza M; Bisagni G; Mosconi AM; Gori S; Boni C; Sabbatini R; Frassoldati A; Passalacqua R; Bian AR; Rodinò C; Rondini E; Algeri R; Di Sarra S; De Angelis V; Cocconi G; Tonato M
Eur J Cancer; 2002 Nov; 38(17):2279-88. PubMed ID: 12441265
[TBL] [Abstract][Full Text] [Related]
15. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
[TBL] [Abstract][Full Text] [Related]
17. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
18. The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions.
Ferreira Filho AF; Di Leo A; Paesmans M; Beauduin M; Vindevoghel A; Michel J; Focan C; Awada A; Cardoso F; Dolci S; Bartholomeus S; Piccart MJ
Ann Oncol; 2002 Mar; 13(3):416-21. PubMed ID: 11996473
[TBL] [Abstract][Full Text] [Related]
19. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
Jonat W; Kaufmann M; Sauerbrei W; Blamey R; Cuzick J; Namer M; Fogelman I; de Haes JC; de Matteis A; Stewart A; Eiermann W; Szakolczai I; Palmer M; Schumacher M; Geberth M; Lisboa B;
J Clin Oncol; 2002 Dec; 20(24):4628-35. PubMed ID: 12488406
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.
Amadori D; Silvestrini R; De Lena M; Boccardo F; Rocca A; Scarpi E; Schittulli F; Brandi M; Maltoni R; Serra P; Ponzone R; Biglia N; Gianni L; Tienghi A; Valerio MR; Bonginelli P; Amaducci L; Faedi M; Baldini E; Paradiso A
Breast Cancer Res Treat; 2011 Feb; 125(3):775-84. PubMed ID: 21132360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
